control groups
[용어속성] Term
The Efficacy of Famotidine in improvement of outcomes in Hospitalized COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial
입원한 COVID-19 환자의 결과 개선에 대한 파모티딘의 효능: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] Alanine
Alanine transaminase
alcoholism
All participant
All participants
allergies
allergy
allocation
approved
ARMS
aspartate
Aspartate transaminase
assigned
assumption
Bandar Abba
Bandar Abbas
baseline
Blinding
block randomization
blood count
Care
Chronic kidney disease
clearance
clinical
clinical trial
clinical trials
code
Committee
company
comparator
Comparator group
complete blood count
concealed
control group
control groups
COVID-19
COVID-19 patient
COVID-19 patients
creatinine
creatinine clearance
criteria
Dasatinib
dialysis
discharge
dissemination
dosage
drug therapy
electrocardiogram
element
eligibility criteria
End-stage renal disease
ethics committee
Evidence
evidence of
excluded
expected
Famotidine
G6PD
Glucose
Glucose 6 phosphate
grouping
groups
Hepatitis
hepatitis C
Hospitalized
Immunocompromised
Immunocompromised patients
Infection
Intervention
Kidney disease
Lactate
lactate dehydrogenase
lead
limit
Liver disease
Local
lung infiltration
maximum
Medical Science
Medical Sciences
moderate
need for dialysis
Neratinib
normal limit
number
objective
online tool
oral contraceptives
outcome
outcome assessor
outcome assessors
oxygen
oxygen saturation
Ozanimod
participant
Patient
patients
patients with COVID-19
Pazopanib
PCR test
pharmaceutical
Pharmaceutical Company
phosphate
Placebo
placebo-controlled
porphyria
positive
Pregnancy
protocol
psoriasis
random
randomisation
randomised
randomised controlled trial
randomized clinical trial
Randomly
randomly divided
receive
recruitment
Registered
registry
renal
renal disease
renal failure
reported
Research question
researcher
respiration rate
responsible
Rilpivirine
Sample size
sample size calculation
sequence
sequence information
single-blind
Siponimod
Standard
study drug
Study protocol
subject
submitted
technology
temperature
the ethics committee
therapy
title
Tizanidine
transaminase
Treatment
treatment group
Treatment protocol
treatment protocols
Trial registration
two group
two groups
university
Version
website
were measured
written consent
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04773-6 PMC 바로가기 [Article Type] Letter
Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review
Original Paper
[키워드] 95% CI
95% CIs
acute kidney failure
acute renal failure
adjusted odds ratio
age
Analysis
baseline
C-reactive protein (CRP
calculate
Care
chart
clinical benefit
clinical effectiveness
Clinical outcome
cohort of patient
Comorbidities
Comorbidity
control group
control groups
COVID-19
COVID-19 diagnosis
COVID-19 pandemic
data-driven guideline
determine
dialysis
discharge
drug
Efficacy and safety
estimates
evaluate
Evidence
global pandemic
group
groups
HCQ
hospital
Hospitalization
hospitalized patient
Hydroxychloroquine
in-hospital mortality
initial
Intensive
intensive care
Invasive mechanical ventilation
mean difference
medication
multivariate logistic regression
no significant difference
objective
Odds ratio
offered
Patient
patients with COVID-19
performed
Randomized controlled trial
reduction in
reductions in
Result
retrospective cohort study
review
significantly higher
T Test
TCZ
Tocilizumab
Trial
use of hydroxychloroquine
was performed
with COVID-19
[DOI] 10.2196/21758 PMC 바로가기 [Article Type] Original Paper
[DOI] 10.2196/21758 PMC 바로가기 [Article Type] Original Paper
Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
Narrative Review
Published on
Journal: Clinical microbiology and infection : the official [Category] MERS, SARS, 치료법,
Journal: Clinical microbiology and infection : the official [Category] MERS, SARS, 치료법,
[키워드] acute respiratory syndrome
administration
adverse events
Alter
antibody
antivirals
article
benefit
candidate
clinical
Clinical outcome
clinical trial
content
control groups
convalescent
convalescent patient
convalescent plasma
coronavirus
coronavirus disease
Coronavirus-2
Coronaviruses
Course
COVID-19
Critically ill patient
described
determine
Donor
effective
Efficacy and safety
Evidence
feasibility
FIVE
follow-up time
had more
high risk
humans
Infection
lack of randomization
limitations
MERS
MERS-CoV
middle
MOST
objective
other treatments
outbreak
outcomes
Pandemics
patient selection
plasma
preliminary trial
randomized clinical trial
randomized control trial
Randomized control trials
recipient
Registered
registry
Research
respiratory syndrome coronavirus
sample sizes
SARS-CoV
SARS-CoV-2
searched
severe disease
short-lived
Source
steroid
Still
therapeutic option
titres
treat
Treatment
treatment for COVID-19
was performed
World Health Organization
[DOI] 10.1016/j.cmi.2020.08.005 PMC 바로가기 [Article Type] Narrative Review
[DOI] 10.1016/j.cmi.2020.08.005 PMC 바로가기 [Article Type] Narrative Review
Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial
Letter
[키워드] 1:1
absence
Admission
Alanine transaminase
assigned
Black seed
Blinding
block
Breast feeding
Chronic kidney disease
chronic liver disease
clinical trial
clinically
comparator
computer-generated randomization
conducted
control group
control groups
COVID-19
COVID19
Date
defined
dialysis
disease
dissemination
Efficacy
element
eligible patient
exploratory
glomerular filtration rate
hospital
Infection
intensive care
Jeddah
King
limit
medication
Mild
Nigella Sativa
no symptoms
number
objective
Open-label
outcome
parallel-group
participant
Patient
phytotherapy
Pneumonia
polymerase chain reaction
Prospective
protocol
radiological
randomisation
randomised
randomised controlled trial
Randomly
recruited
renal
respiratory
Sample size
SARS-CoV-2
Saudi Arabia
Standard of care
status
Symptom
symptomatic mild
the patient
throat swab
transfer
treat
Treatment
Trial
Two-arm
university
upper respiratory tract
website
written Informed Consent
[DOI] 10.1186/s13063-020-04647-x PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04647-x PMC 바로가기 [Article Type] Letter
Contribution of acute-phase reaction proteins to the diagnosis and treatment of 2019 novel coronavirus disease (COVID-19)
Original Paper
[키워드] 2019 novel coronavirus
Acute phase reaction protein
approach
Asymptomatic
Blood
C-reactive protein
change
changes in
Clinical management
community-acquired pneumonia
complement
control groups
control subject
COVID-19
COVID-19 group
COVID-19 patient
COVID-19 patients
CRP
detect
Diagnosis
disease
expression level
fasting
identify
immunological characteristics
IMPROVE
indicated
Mild
moderate
Patient
prealbumin
Prognosis
progression
Protein
provided
recruited
SAA
serum
serum amyloid
serum amyloid A
severe patients
significant increase
significantly
statistical analysis
Study design
suggested
symptomatic patient
the mean
Treatment
venous
with COVID-19
[DOI] 10.1017/S095026882000165X PMC 바로가기 [Article Type] Original Paper
[DOI] 10.1017/S095026882000165X PMC 바로가기 [Article Type] Original Paper
Efficacy of local budesonide therapy in the management of persistent hyposmia in COVID-19 patients without signs of severity: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
addition
alveolar
association
blinded
breastfeeding women
Budesonide
cause
chest CT scan
close contact
Control
control groups
Corticosteroid
COVID-19
COVID-19 patient
criteria
CYP3A4 inhibitor
disorder
dissemination
dysgeusia
Efficacy
element
form
France
HIV
hypersensitivity
Hyposmia
Inclusion
intranasal
Local
Loss of Smell
management
MRI
nasal
Nasal Irrigation
nodule
number
objective
olfactory
onset of symptom
onset of symptoms
Open-label
ophthalmic
Other
outcome
parallel group
Paris
participant
Patient
patients
PCR
PCR-confirmed
percentage
physiological saline
positive serology
protease
protocol
randomised
randomised controlled trial
randomization list
Randomized
recruited
Registered
rehabilitation
Rothschild
rotocol
Sample size
SARS-CoV-2
SARS-COV-2 infection
severity
status
stratified
Study protocol
therapy
Treatment
Trial
two group
Version
virus
website
[DOI] 10.1186/s13063-020-04585-8 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04585-8 PMC 바로가기 [Article Type] Letter
Rate of venous thromboembolism in a prospective all-comers cohort with COVID-19
Article
[키워드] Admission
Analysis
analyzed
association
clinical complication
Coagulopathy
Cohort
Control
control group
control groups
correlated
Course
courses
COVID-19
COVID-19 group
critically ill patients
D-dimer
D-dimers
diagnosed
disease
disease severity
evaluate
Follow-up
follow-up period
ICU
in both group
Mortality
occurred
Patient
positive
presenting
Rate
reported
SARS-CoV-2
severity
single-center study
statistically significant
Symptoms
variety
Venous Thromboembolism
VTE
with COVID-19
[DOI] 10.1007/s11239-020-02202-8 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s11239-020-02202-8 PMC 바로가기 [Article Type] Article
Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)
중증 COVID-19 환자를 치료하기 위한 동종 인간 치수 줄기세포의 안전성 및 효능 평가: 무작위 대조 시험(I/II상)을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
Acidic
Adenovirus
Admission
AIDS
Alanine
alanine aminotransferase
albumin
alkaline phosphatase
Allogeneic
allogeneic human dental pulp stem cells
amyloid
Analysis
anion gap
Arm ratio
aspartate
Aspartate aminotransferase
average
B lymphocyte
basophils
Before menopause
Bilirubin
blind
blinded
Block randomization method
Blood
blood cell
Blood cells
blood pressure
Blood routine
C-reactive protein
calcium
carbon dioxide
Care
CAST
caused
Cell
cell suspension
change
chest X-ray
Child Pugh score
chlorine
cholesterol
cholinesterase
CLARITY
clinical
Clinical improvement
clinical trial
coded
Coefficient of variation
color
commenced
comparator
computer
Concentration
Consent
consent form
Continuous renal replacement therapy
control group
control groups
COVID-19
COVID-19; randomised controlled trial; protocol; human dental pulp stem cells; dental stem cell banking
COVID-2019
creatine
creatine kinase
creatinine
criteria
crystal
Cytokines
cytomegalovirus
cytomegalovirus CMV-IgG
cytomegalovirus CMV-IgM
Definition
dental pulp
dental pulp stem cells
description
detect
Diastolic blood pressure
direct bilirubin
discharge
disease
dissemination
distress
distribution
DPSCs
ECMO
Efficacy
element
enrolled
eosinophil
eosinophils
epithelial cells
estimated glomerular filtration rate
Estrogen
examined
excluded
exclusion criteria
experimental group
fat globules
Female patients
female subject
filtration rate
Final
flow cytometry
follow-up period
fungi
fungus
Globulin
glomerular filtration rate
Glucose
GRADE
Grade 1
grade 3
Grade 5
granulocyte
HBcAb
HBeAb
HBeAg
HBsAb
HBsAg
hDPSCs
Health Organization
heart rate
hematocrit
Hemodialysis
hemoglobin
hepatitis B
hepatitis C
HFNC
high density lipoprotein
hospitalised patient
Hospitalised patients
Hospitalization
Hospitalized
human DPSC
human DPSCs
hypersensitive C-reactive protein
hypoxia
Identifier
IgA
IgG
IgM
Il -10
IL-1
IL-1 β
IL-2
IL-4
IL-6
immune
Immunoglobulin
Immunological testing
improvement
IMV
inclusion criteria
Infectious disease
Influenza
Influenza virus
informed consent form
injection
Injections
intensive care
intensive care unit
Intravenous injection
Invasive mechanical ventilation
investigator
investigators
ITN-γ
ketone
ketone bodies
Kidney function
Kidney function tests
Killer cell
Laboratory
laboratory examinations
Lactate
lactate dehydrogenase
lactating women
leukocyte
leukocyte enzymes
lipoprotein
lipoprotein A
lipoprotein cholesterol
low density lipoprotein
lung lesion
lung lesions
lymphocyte
Lymphocytes
Macrophage
Magnesium
Medical care
Menopause
Monocytes
mononuclear cell
mononuclear cells
nasal
nasal catheter
natural killer
natural killer cell
neutrophil
Neutrophils
nitrite
NIV
Non-invasive
non-invasive mechanical ventilation
non-squamous epithelial cell
non-squamous epithelial cells
nucleic acid
nucleic acid test
number
objective
observation
occult
occult blood
Other
Other condition
outcome
oxygen
oxygen saturation
parallel group
parasites
partial pressure
participant
Patient
penetration
performed
Peripheral blood
Peritoneal dialysis
phase
phenotype
phosphatase
phosphorus
Placebo
placebo-controlled
Platelet
Platelet count
platelet distribution width
Platelets
Potassium
prealbumin
pregnancy test
pregnant
pressure
Primary outcome
Protein
protocol
random
randomisation
randomization
Randomized
Randomized controlled trial
receive
receiving
recruitment
red blood cell
red blood cells
renal
renal insufficiency
renal replacement therapy
Renmin Hospital
replacement therapy
required
researcher
respiratory
respiratory distress
respiratory infection
respiratory rate
Safety
Saline
saline solution
Sample size
SARS-CoV-2
secondary
Secondary outcomes
serious COVID-19
serum
serum amyloid
severe liver condition
severe pneumonia
single-cell analyses
sodium
specific gravity
Standard deviation
status
stem cell
study period
Study protocol
sugar
syphilis
Systolic blood pressure
T lymphocyte
Th1 cytokine
Th1 cytokines
Th2 cytokine
Th2 cytokines
therapeutic effect
therapeutic effects
time
TNF-a
Total
total bilirubin
Total cholesterol
total protein
traits
Transferrin
treat
Treatment
treatment for COVID-19
triacylglycerol
Trial
triple blinded
TTCI
Tuberculosis
Twenty participant
Twenty participants
university
urea
uric acid
Urine
urobilinogen
Variation
Version
vital signs
Volume
website
White blood cells
with HIV
within 6 months
women
World Health Organization
Wuhan
γ-glutamyl transferase
[DOI] 10.1186/s13063-020-04380-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04380-5 PMC 바로가기 [Article Type] Letter
Oral immunization with a novel attenuated Salmonella Gallinarum encoding infectious bronchitis virus spike protein induces protective immune responses against fowl typhoid and infectious bronchitis in chickens
신형 약화된 살모넬라 갈리나룸을 이용한 경구 면역화가 감염성 기관지염 바이러스 스파이크 단백질을 인코딩하여 닭에서 조류 티푸스와 감염성 기관지염에 대한 보호 면역 반응을 유도한다.
Research Article
[키워드] Affect
Against
bronchitis
caused
Cell-mediated immunity
clone
cloned
control group
control groups
demonstrated
disease
elicit
elicited
exhibited
expression vector
Fowl
group
humoral
IBV
induce
Infectious Bronchitis Virus
Inflammatory
lesion
Mortality
mutant
nucleotide sequence
Oral Immunization
PBS
Plasmid
protective immune response
protective immunity
Protein
Salmonella
shown
significantly
Spike protein
supplementary material
tissue
tracheal
Vaccine
virulent
virus
wild-type
[DOI] 10.1186/s13567-018-0588-9 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1186/s13567-018-0588-9 PMC 바로가기 [Article Type] Research Article